home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Courses and Workshops
Search  -  prev / next
 
 

OTC Stability Program for FDA Compliance

 
  July 06, 2017  
     
 
CfPA-The Center for Professional Advancement, Burlingame, CA
October 19-20, 2017


Who Should Attend?
This course is intended for individuals who have the responsibility for establishing the stability of Over-the-Counter (OTC) drug products. This course will benefit individuals in:

  • R&D 
  • QA/QC
  • Technical Operations 
  • Contract Laboratories

RAPS - Regulatory Affairs Professional Society 
This course has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's recertification of their Regulatory Affairs Certification (RAC) upon full completion. 

Course Description
In 2006, FDA withdrew both their approved 1987 Stability Guideline and their draft 1998 Stability Guidance and referred industry to the ICH Stability Guidances. With the ICH guidance documents covering New Chemical Entities (NCEs) and their associated drug products, there was no guidance provided for OTC drugs covered by an ANDA or OTC monograph. In 2014, FDA issued Guidance for Stability testing requirements for all drug products covered by an ANDA, but no guidance has been provided for OTC monograph drug products.

As a result, strictly following the ICH stability guidance for NCEs is unwarranted and ignores this significant database of information that is typically available for OTC drug products. For OTC drug products covered by an OTC monograph or an ANDA, there is frequently years of proven experience with the drug substance as well as the drug product. It is this body of data that can often be used to justify a pre-market stability program.

This 2-day intensive course will provide an understanding of how the pre-market stability programs can be successfully managed while minimizing the overall timeline. Lectures will address the seven key GMP aspects of a stability program along with all of the relevant ICH, FDA, WHO and CHPA guidelines that cover drug product stability. Accelerated testing that allows the marketing of a new OTC drug product prior to the generation of long term, real time stability data and confirmation of the stability projections through an appropriate post-market stability program will also be covered.
 
 
Organized by: CfPA-The Center for Professional Advancement
Invited Speakers:
 
David E. Wiggins; Sr. Associate Director of Analytical Development, Bayer Consumer Care

David E. Wiggins is Sr. Associate Director of Analytical Development for Bayer Consumer Care with responsibility for pre-market stability, analytical method validation and method transfer.

Prior to joining Bayer, Mr. Wiggins worked for Schering- Plough and Merck with responsibility for Method Optimization, Method Validation, Method Transfer and Stability (both preand post-market). These responsibilities have additionally included involvement with multiple NDA submissions and FDA general and PAI inspections.

Mr. Wiggins has over 30 years experience in the pharmaceutical industry in both a QC and an R&D setting. During this time, he has been instrumental in establishing and updating stability and method validation policy to be consistent with the changing regulatory requirements. Mr. Wiggins has frequently lectured on stability and analytical method validation in the US, Puerto Rico, and throughout Europe. He has been active in submitting comments and validated stability-indicating analytical methods to the U.S. Pharmacopeia and has been an invited speaker to FDA, university, and industry conferences.

Additional Faculty
Karen Lucas, Sr. Manager, Pharmaceutical Quality, Stability Operations,Janssen Pharmaceuticals, Johnson & Johnson

Carmelinda (Jing) Capucao, R&D Stability Manager, McNeil Consumer Products
 
Deadline for Abstracts: n/a
 
Registration: Please click here for registration information.
E-mail: jmorbit@cfpa.com
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

 
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2017 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.